Shire plc announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for VYVANSE for the treatment of Attention Deficit Hyperactivity Disorder in adults.
From: biz.yahoo.com
Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Posted by Ruslan Abuzant at 12:26 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment